1. American Society of Addiction Medicine. (2015). National practice guideline for the use of medications in the treatment of addiction involving opioid use. Available at:https://www.asam.org/docs/default-source/practice-support/guidelines-and-consensus-docs/asam-national-practice-guideline-supplement.pdf%209.
2. A qualitative study comparing physician-reported barriers to treatment addiction using buprenorphine and extended-release naltrexone in U.S. office-based practice;Andraka-Christou;International Journal of Drug Policy,2018
3. Barriers rural physicians face prescribing buprenorphine for opioid use disorder;Andrilla;Ann Fam Med,2017
4. Andrilla, C.H., Coulthard, C., & Larson, E.H. (2017b), Changes in the supply of physicians with a DEA data waiver to prescribe buprenorphine for opioid use disorder. Available.
5. Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users;Bazazi;Journal of Addiction Medicine,2011